• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/2/23 1:31:27 PM ET
    $ANPC
    $AYTU
    $BTCY
    $CADL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANPC alert in real time by email

    Gainers

    • Biotricity (NASDAQ:BTCY) stock rose 30.2% to $0.73 during Tuesday's regular session. Trading volume for Biotricity's stock is 264.8K as of 13:30 EST. This is 121.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $38.3 million.
    • TScan Therapeutics (NASDAQ:TCRX) shares moved upwards by 28.65% to $2.11. As of 13:30 EST, TScan Therapeutics's stock is trading at a volume of 57.1K, which is 136.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.9 million.
    • Immatics (NASDAQ:IMTX) shares rose 26.93% to $9.29. Immatics's stock is trading at a volume of 3.3 million shares as of 13:30 EST. This is 1248.2% of its average full-day volume over the last 100 days. The company's market cap stands at $712.3 million.
    • IN8bio (NASDAQ:INAB) shares rose 22.98% to $2.14. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 40.9% of its average full-day volume over the last 100 days. The company's market cap stands at $53.3 million.
    • SenesTech (NASDAQ:SNES) stock increased by 20.82% to $1.46. As of 13:30 EST, this security is trading at a volume of 262.9K shares, making up 79.5% of its average full-day volume over the last 100 days. The company's market cap stands at $4.3 million.
    • Candel Therapeutics (NASDAQ:CADL) stock increased by 20.58% to $1.64. As of 13:30 EST, this security is trading at a volume of 78.6K shares, making up 270.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $47.4 million.

    Losers

    • Community Health Sys (NYSE:CYH) stock fell 36.4% to $3.96 during Tuesday's regular session. The current volume of 5.4 million shares is 231.6% of Community Health Sys's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $542.2 million. The company's, Q1 earnings came out yesterday.
    • Jin Medical International (NASDAQ:ZJYL) stock decreased by 35.53% to $6.19. Jin Medical International's stock is trading at a volume of 183.3K shares as of 13:30 EST. This is 305.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $47.9 million.
    • Travere Therapeutics (NASDAQ:TVTX) stock fell 33.49% to $15.04. Trading volume for Travere Therapeutics's stock is 5.4 million as of 13:30 EST. This is 361.8% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion.
    • Aytu BioPharma (NASDAQ:AYTU) stock declined by 27.47% to $1.69. The current volume of 277.6K shares is 403.2% of Aytu BioPharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $6.3 million.
    • Scilex Holding (NASDAQ:SCLX) stock fell 22.63% to $4.65. The current volume of 469.1K shares is 72.6% of Scilex Holding's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $678.0 million.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares declined by 20.92% to $5.18. The current volume of 133.2K shares is 752.1% of AnPac Bio-Medical Science's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $29.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANPC
    $AYTU
    $BTCY
    $CADL

    CompanyDatePrice TargetRatingAnalyst
    Immatics N.V.
    $IMTX
    3/16/2026Buy
    Jefferies
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Travere Therapeutics Inc.
    $TVTX
    10/31/2025$34.00 → $48.00Buy
    Citigroup
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Immatics N.V.
    $IMTX
    9/18/2025$16.00Buy
    Guggenheim
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Community Health Systems Inc.
    $CYH
    7/24/2025$3.00Buy → Hold
    Jefferies
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    More analyst ratings

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Reinhardt Carsten Alexander Johannes

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:41:57 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Britten Cedrik Michael

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:39:50 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sturchio Edward A Jr

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:39:40 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Immatics N.V.

    Jefferies resumed coverage of Immatics N.V. with a rating of Buy

    3/16/26 9:36:08 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded TScan Therapeutics from Overweight to Equal-Weight

    11/14/25 10:24:29 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup reiterated coverage on Travere Therapeutics with a new price target

    Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously

    10/31/25 10:57:06 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

    Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert

    3/17/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties

    PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has filed a complaint (the "Complaint") in the United States District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd. ("St. James Bank"), Omega & Corinth Group Ltd., and related parties (collectively, the "Wade Defendants"), alleging a scheme involving the unauthorized tr

    3/13/26 11:16:18 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $AYTU
    $BTCY
    $CADL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    3/18/26 5:23:43 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

    6-K - Jin Medical International Ltd. (0001837821) (Filer)

    3/17/26 4:30:16 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Community Health Systems Appoints Kevin Hammons Chief Executive Officer and Jason Johnson Chief Financial Officer

    Community Health Systems, Inc. (NYSE:CYH) (the "Company" or "CHS") announced today that the Company's Board of Directors has appointed Kevin Hammons to chief executive officer and Jason Johnson to chief financial officer, effective immediately. Hammons and Johnson have been serving in these roles on an interim basis since October 1, 2025. Hammons was also appointed to serve as a member of the Board. "I'm honored to lead the CHS team during a time when we see significant opportunities to advance clinical services, quality and patient care, deeply engage with employees and physicians, and create lasting value for all of our communities and stakeholders," said Kevin Hammons, chief executive o

    12/10/25 4:15:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ANPC
    $AYTU
    $BTCY
    $CADL
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

    2/19/26 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care